Sarepta Therapeutics (SRPT) Competitors $21.43 -0.53 (-2.41%) Closing price 04:00 PM EasternExtended Trading$21.46 +0.02 (+0.12%) As of 05:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SRPT vs. CTMX, EDIT, RVMD, CYTK, MRUS, RNA, GRFS, ABVX, RYTM, and CRSPShould you be buying Sarepta Therapeutics stock or one of its competitors? The main competitors of Sarepta Therapeutics include CytomX Therapeutics (CTMX), Editas Medicine (EDIT), Revolution Medicines (RVMD), Cytokinetics (CYTK), Merus (MRUS), Avidity Biosciences (RNA), Grifols (GRFS), Abivax (ABVX), Rhythm Pharmaceuticals (RYTM), and CRISPR Therapeutics (CRSP). These companies are all part of the "pharmaceutical products" industry. Sarepta Therapeutics vs. Its Competitors CytomX Therapeutics Editas Medicine Revolution Medicines Cytokinetics Merus Avidity Biosciences Grifols Abivax Rhythm Pharmaceuticals CRISPR Therapeutics Sarepta Therapeutics (NASDAQ:SRPT) and CytomX Therapeutics (NASDAQ:CTMX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends. Do institutionals & insiders hold more shares of SRPT or CTMX? 86.7% of Sarepta Therapeutics shares are held by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are held by institutional investors. 7.6% of Sarepta Therapeutics shares are held by insiders. Comparatively, 6.6% of CytomX Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has stronger valuation & earnings, SRPT or CTMX? Sarepta Therapeutics has higher revenue and earnings than CytomX Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSarepta Therapeutics$1.90B1.10$235.24M-$0.87-24.63CytomX Therapeutics$138.10M4.08$31.87M$0.566.11 Do analysts rate SRPT or CTMX? Sarepta Therapeutics presently has a consensus price target of $34.42, suggesting a potential upside of 60.60%. CytomX Therapeutics has a consensus price target of $5.42, suggesting a potential upside of 58.38%. Given Sarepta Therapeutics' higher probable upside, research analysts plainly believe Sarepta Therapeutics is more favorable than CytomX Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sarepta Therapeutics 7 Sell rating(s) 14 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.03CytomX Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is SRPT or CTMX more profitable? CytomX Therapeutics has a net margin of 34.04% compared to Sarepta Therapeutics' net margin of -2.34%. CytomX Therapeutics' return on equity of 158.70% beat Sarepta Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sarepta Therapeutics-2.34% -1.03% -0.37% CytomX Therapeutics 34.04%158.70%36.04% Which has more volatility & risk, SRPT or CTMX? Sarepta Therapeutics has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 2.27, suggesting that its share price is 127% more volatile than the S&P 500. Does the media prefer SRPT or CTMX? In the previous week, Sarepta Therapeutics had 5 more articles in the media than CytomX Therapeutics. MarketBeat recorded 13 mentions for Sarepta Therapeutics and 8 mentions for CytomX Therapeutics. Sarepta Therapeutics' average media sentiment score of 0.89 beat CytomX Therapeutics' score of 0.78 indicating that Sarepta Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sarepta Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CytomX Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryCytomX Therapeutics beats Sarepta Therapeutics on 9 of the 17 factors compared between the two stocks. Get Sarepta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SRPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SRPT vs. The Competition Export to ExcelMetricSarepta TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.09B$3.36B$6.02B$10.45BDividend YieldN/A2.31%5.73%4.82%P/E Ratio-24.6322.0385.1227.23Price / Sales1.10470.42589.70134.52Price / Cash9.0844.9825.7730.18Price / Book1.3410.4312.676.76Net Income$235.24M-$52.58M$3.32B$276.50M7 Day Performance-7.31%0.98%0.49%0.85%1 Month Performance23.23%14.77%9.41%8.16%1 Year Performance-82.77%21.29%79.11%43.62% Sarepta Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SRPTSarepta Therapeutics4.6315 of 5 stars$21.43-2.4%$34.42+60.6%-82.4%$2.09B$1.90B-24.631,372Analyst ForecastGap UpCTMXCytomX Therapeutics4.2375 of 5 stars$3.28-0.6%$5.42+65.1%+195.7%$540.91M$138.10M5.86170EDITEditas Medicine4.2732 of 5 stars$3.80-3.1%$5.10+34.2%+11.6%$341.70M$32.31M-1.33230Gap DownRVMDRevolution Medicines4.1125 of 5 stars$46.58-0.3%$74.64+60.2%-3.4%$8.71B$11.58M-10.35250CYTKCytokinetics3.6747 of 5 stars$60.64+6.4%$76.64+26.4%+8.6%$7.26B$18.47M-11.89250MRUSMerus0.9058 of 5 stars$94.270.0%$93.12-1.2%+77.6%$7.13B$36.13M-17.1437High Trading VolumeRNAAvidity Biosciences1.9964 of 5 stars$46.18-1.7%$68.32+47.9%+5.1%$6.74B$10.73M-12.97190Gap DownGRFSGrifols3.7549 of 5 stars$9.61-3.4%$10.30+7.2%+10.0%$6.61B$7.81B8.2123,822Analyst DowngradeABVXAbivax2.6772 of 5 stars$86.67+3.3%$102.14+17.9%+904.5%$6.55BN/A0.0061Analyst ForecastHigh Trading VolumeRYTMRhythm Pharmaceuticals3.119 of 5 stars$97.86-1.2%$106.64+9.0%+102.3%$6.50B$130.13M-32.51140Positive NewsCRSPCRISPR Therapeutics1.6567 of 5 stars$70.19+3.6%$71.50+1.9%+45.8%$6.38B$37.31M-12.93460Analyst Forecast Related Companies and Tools Related Companies CytomX Therapeutics Competitors Editas Medicine Competitors Revolution Medicines Competitors Cytokinetics Competitors Merus Competitors Avidity Biosciences Competitors Grifols Competitors Abivax Competitors Rhythm Pharmaceuticals Competitors CRISPR Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SRPT) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | SponsoredWhat Wall Street Won’t Say Out LoudDiscover the 7 key indicators before everyone else doesAmerican Alternative | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sarepta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
